

Aurobindo Pharma

BSE SENSEX

30,126

S&P CNX

9,360



Stock Info

Bloomberg	ARBP IN
Equity Shares (m)	586
52-Week Range (INR)	895 / 582
1, 6, 12 Rel. Per (%)	-14/-29/-47
M.Cap. (INR b)	347.0
M.Cap. (USD b)	5.4
Avg Val, INRm	1605
Free float (%)	48.1

Financials Snapshot (INR b)


Y/E Mar	2017E	2018E	2019E
Net Sales	151.7	174.9	199.3
EBITDA	35.8	41.8	48.8
PAT	23.3	26.6	31.8
EPS (INR)	39.8	45.4	54.3
Gr. (%)	17.5	14.1	19.7
BV/Sh (INR)	157.9	200.8	252.6
RoE (%)	28.6	25.3	24.0
RoCE (%)	19.5	19.4	19.5
P/E (x)	14.9	13.0	10.9
P/BV (x)	3.7	2.9	2.3

Shareholding pattern (%)

As On	Mar-17	Dec-16	Mar-16
Promoter	51.9	51.9	53.8
DII	12.8	11.0	7.3
FII	21.0	24.1	27.4
Others	14.4	13.0	11.5

FII Includes depository receipts

Stock Performance (1-year)


CMP: INR592
TP: INR900(+52%)
Buy

Positives outweigh risks – time to accumulate

- USFDA inspections not a cause of concern:** Aurobindo Pharma's (ARBP) Unit 3 (oral solids; ~USD200m sales) and Unit 4 (injectables; ~USD100m of sales) facilities received six and seven observations, respectively, following the USFDA inspection in April 2017. Unit 3 observations are already out – there are no data integrity issues, with all the observations being procedural in nature. Unit 4 was previously inspected in September 2016 and received EIR in February this year. The inspection was triggered as ARBP added a new block in the facility. According to the company, all the observations at Unit 4 are procedural (letter should be out in coming few days).
- Lower tax rate in US bodes well; risk mitigation strategy in place for border tax:** The US government has proposed to lower the corporate tax rate from 35% to 15%. The company's US subsidiaries generated PBT of INR5b in FY16 and paid tax @32% of PBT. If the tax rate in the US comes down to 15%, then ARBP will save >INR1b in FY17/18E (EPS of ~INR1.8-2). On the other hand, border tax adjustment is a key overhang to the generic suppliers. We believe ARBP can mitigate this risk partially by expanding its Auro Life facility (can go 3x by doing brownfield expansion).
- Pricing risk lowest among peers:** No single product for ARBP contributes more than 3% of sales (unlike SUNP, LPC and DRRD, where the top three products account for >20-25% of sales). Also, no single ANDA has any meaningful disproportionate contribution to margins, as ARBP has a matured product basket with all ~190 launched ANDAs facing competition from multiple players (typically 4-5 or more).
- R&D expense to remain range bound in near term:** We expect ARBP to file 35-40 ANDAs in FY18E (including 6-7 controlled substance, 10-15 oncology & hormones, etc.). Oncology & hormones-related R&D expense will be borne by the Eugia JV, and will not be part of R&D expense for ARBP. We expect R&D expense for the company to not inch up beyond 5.5% in FY18E and 7% in FY19E. Impact of this increase in expense will get offset by ~50% growth in the high-margin injectables business.
- Commissioning of key plants to drive volume growth in FY18/19E:** Over next 6-9 months, three key formulation plants are getting commissioned, including Vizag (dedicated supply to EU started in March 17), Unit XVI (antibiotic injectable plant to supply products in the US) and Naidupet (oral solids plant to supply to the US). Commissioning of the Vizag plant will have a two-pronged impact: 1) Capacity at Unit VII and Unit III will get released (which are primarily used for supply to the US, and are running at capacity utilization of ~80%). 2) European business margin should expand (to ~7-8% in FY18E from ~5% currently) as the company plans to manufacture 50% of products sold in EU at this plant. The Naidupet plant will get commissioned by mid-FY18E, and will be one of the largest formulations plants for ARBP (with capacity of 7-8b tablets).


- **Strong launch pipeline, coupled with volume push, to drive growth:** ARBP received 49 and 47 ANDA approvals in FY16 and 9MFY17, respectively (highest in the industry). We expect this strong approval and launch momentum to continue on the back of ~159 pending ANDAs. We expect ARBP to deliver mid-teens growth in the US, led by its strong launch pipeline in injectables (~40 pending ANDAs), steady mid-teens growth in Natrol, and huge capacity expansion in orals and injectables (which will lead to volume push in existing as well as new products). We expect a pick-up in US sales over coming quarters, driven by key launches such as Epzicom, Meropenem, Tenofovir, Toprol XL and Fortamet and Solu-Medrol. Apart from this, ARBP has an approved pipeline of ~50 products (~13 OTCs, 5-6 OTCs, 6 injectables, rest orals including Vancomycin), which will be launched by 2QFY18.
- **EU and ARV business can surprise positively in FY18E/19E:** Manufacturing of ~60 products has been shifted to India from EU (to Unit VII & III). Given that supply from Vizag to EU markets has started from March 2017, the company plans to shift manufacturing of ~114 products from Vizag (sales value of >USD200m) over next 12-18 months, leading to significant cost savings. We expect EBITDA margin of this business to expand from ~5% currently to ~7-8% in FY18E and to low-double-digits in FY19E. ARV business growth in FY19 will be driven by a pick-up in DTG triple combination approvals (USD500m market).
- **Strong earnings growth trajectory and improving cash flow to drive valuations:** At its CMP, ARBP trades at <15x FY17E, which is at >25% discount to its peers. The valuation gap is expected to narrow on account of the company's increasing profitability, strong earnings growth trajectory (17% CAGR until FY19E) and improving free cash flow. ARBP remains one of our top picks in the sector, with a target price of INR900 @ 18x 1HFY19E PER (v/s INR915 @ 18x 1HFY19E earlier). We cut our FY18/19E EPS by 6/5% as we build the impact of pricing pressure in the US.

US business – strong growth to sustain

US business to record mid-teens CAGR

Over FY11-16, ARBP delivered robust >50% CAGR, driven by niche oral launches (including Cymbalta) and entry into injectables, controlled substances and government tender business. Despite strong growth over the last five years, we believe ARBP is well poised to outpace peers in the coming years. We expect ARBP to deliver mid-teens growth in the US on the back of a strong launch pipeline in injectables (~40 pending ANDAs), steady mid-teens growth in Natrol and huge capacity expansion in orals and injectables (which will lead to volume push in existing and new products). We expect a pick-up in US sales over the coming quarters led by key launches, including Epzicom, Meropenem, Tenofovir, Toprol XL and Fortamet, Solu-Medrol. Apart from this, ARBP has an approved pipeline of ~50 products (~13 OTCs, 5-6 OTCs, 6 injectables, rest orals including Vancomycin), which are expected to be launched in 2QFY18.

Exhibit 1: US business to grow at ~14%YoY



Source: Company, MOSL

Lower tax rate in US bodes well; risk mitigation strategy in place for border tax

The US government has proposed to lower the corporate tax rate from 35% to 15%. The company's US subsidiaries generated PBT of INR5b in FY16 and paid tax @32% of PBT. If the tax rate in the US comes down to 15%, then ARBP will save >INR1b in FY17/18E (EPS of ~INR1.8-2). On the other hand, border tax adjustment is a key overhang to the generic suppliers. We believe ARBP can mitigate this risk partially by expanding its Auro Life facility (can go 3x by doing brownfield expansion).

Exhibit 2: US subsidiaries' contribution to ARBP

Name of the Subsidiary	Sales	PBT	Tax	PAT
Aurobindo Pharma USA Inc	34,945.50	1,080.60	350.3	730.3
Aurolife Pharma LLC	9,215.80	2,605.30	844.6	1,760.70
Auromedics Pharma LLC	6,305.00	406.5	131.8	274.7
Auro Health LLC	259.4	-220.8	-71.6	-149.2
Natrol Inc	7,367.80	1,122.90	364	758.8
Total US subsidiaries	58,093.50	4,994.50	1,619.10	3,375.30
Consolidated ARBP	138,960.80	27,224.70	7443.7	19,820.10
US as % of ARBP	41.8%	18.3%	21.8%	17.0%

Source:

Burst of approvals provides strong visibility of future growth

ARBP received 49 and 47 ANDA approvals in FY16 and 9MFY17, respectively (highest in the industry). The approvals are a mix of plain vanilla generics, limited competition injectables and complex oral generics. Out of the pending injectables portfolio of ~40 ANDAs, most were filed 12-24 months back. We thus expect multiple injectables approvals to come through over the next two years.

Exhibit 3: Robust ANDA pipeline




Exhibit 4: Highest number of approvals amongst peers





Exhibit 5: Unit-wise ANDA filings as on 31-Dec-2016

Unit	Details	Final Approval		Tentative Approval		Under Review		Total	
		Mar-16	Dec-16	Mar-16	Dec-16	Mar-16	Dec-16	Mar-16	Dec-16
III	Oral Formulations	93	99	19	16	12	10	124	125
IV	Inj & Ophthalmics	28	38	2	2	37	35	67	75
VI B	Ceph Oral	11	11					11	11
VII (SEZ)	Oral Formulations	54	79	15	23	79	56	148	158
X	Oral Formulations						2		2
XII	Penicillin Oral & Inj	19	19				1	19	20
Auro Life USA	Oral Formulations	10	16			16	10	26	26
Auronext	Penem Inj					3	4	3	4
Total		215	262	36	41	147	118	398	421

Exhibit 6: Expanding portfolio mix toward high-value products




European operations – Commencement of Vizag facility to lead to margin expansion

ARBP has expanded its Europe business inorganically. Till date, it has acquired 5-6 businesses in Europe (Milopharm in 2006, Pharmacin in 2007, Actavis in 2014, Generis & Teva businesses in 2016). After these acquisitions, ARBP has become one of the top 10 players in EU. Supplies from the Vizag plant to Europe will start from March-17. This will have a two-pronged impact: 1) capacity at Unit VII and Unit III will get released (which are primarily used for supply to the US and are running at capacity utilization of ~80%) and 2) European business margins should expand (to ~7-8% in FY18E from ~5% currently) as the company plans to manufacture 50% of products sold in EU at this plant.


Currently, manufacturing of ~60 products has been shifted to India (to Unit VII & III). Given that supply from Vizag to EU markets will start from Mar-17, the company plans to shift manufacturing of ~114 products from Vizag (sales value of >USD200m) over next 12-18 months. This will lead to significant cost savings. We expect EBITDA margins of this business to expand from ~5% currently to ~7-8% in FY18 and low-double-digits in FY19.

Exhibit 7: EU growth bolstered by Actavis acquisition




Source: Company, MOSL

Exhibit 8: Sales split by Channel




Source: Company, MOSL

Exhibit 9: Sales split by Therapeutic Profile



Source: Company, MOSL

Exhibit 10: Sales split by Dosage Forms



Source: Company, MOSL

Exhibit 11: EU: Portfolio mix across channels

Channels	Gx	BGx	Hx	TGx
Geographies	All 9 countries	7 countries	All 9 countries	Germany, Spain & Netherlands
# of Products	761 (Primarily tablets & capsules) 34		343 (predominantly Inj)	765 (Including Gx products)
Other Highlights	Amongst top 10 in most markets	Includes leading brands such as Neotigason, Floxapen, Bezalip among others	Focus on high value areas including oncology	Tender based business

Portugal acquisition to provide market leadership: With Generis acquisition (announced in Jan-17), ARBP gets a well-diversified portfolio (primarily in the area of Cardio – 26% of sales, CNS – 22% and anti-infectives – 13%), addressing 95% of the generic retail market by value with 227 products + 51 products awaiting approval. Post completion of this acquisition, ARBP will become number 1 player in the Portugal market and among the top 10 generic companies in EU (from no. 13 earlier). Portugal's pharma market size stands at EUR3.4b, with generic penetration in volume at ~30%, significantly below EU average of ~53% and US average of ~80%.

Estimated sales of Generis stood at EUR64.8m in CY16 (largely remained flat over last three years), with EBITDA of EUR12.7m (EBITDA margin of ~19.6% v/s ARBP's EU biz margin of mid-single-digits). ARBP expects sales growth of >12% in CY17 with improved EBITDA margin of 21.7%. Improvement in profitability is expected on the back of new launches and resolution of temporary supply chain issues from third party in 2016.

ARBP expects synergy benefits of EUR2m and EUR5m in 2018 and 2019, respectively (and expected to improve further). This will be primarily driven by new product portfolio launch, market leadership status and improvement in capacity utilization.

With this acquisition, ARBP will have its first formulations plant in EU (with capacity of 1.2b tablets/ capsules/ sachets). Existing plant capacity is at ~50%, which provides ample room for growth. Deeper penetration in Portugal markets and ability to capture untapped business opportunities in other EU markets will help the company improve its capacity utilization to ~80% by 2020.

At deal value of EUR135m, this transaction is valued at 10.5x and 8.5x CY16 and CY17 EV/ EBITDA, respectively. Despite the acquisition of businesses in Portugal and France, ARBP should end FY17 with net debt of <USD600m (with net debt/equity of ~0.55- 0.6x), at par with FY16.

Dolutegravir (DTG) – the next growth driver

- ARBP is the first generic company to sign license with ViiV Healthcare for the next generation Integrase Inhibitor – DTG.
 - Filed an ANDA application for DTG 50mg with USFDA under the PEPFAR program.
 - WHO announced this drug as a first line reserve drug in its 2015 HIV treatment guidelines.
 - Play a collaborative role in upgrading millions of patients to the latest best in-class ARV drug.
- Developing a triple drug combination containing DTG.
- Market size is expected to be USD2b in 2017; Triple combination drug containing DTG expected to garner major share.

Valuation and view

ARBP has outperformed most pharma peers over past 12 months, driven by a significant improvement in its operating performance post clearance of USFDA import alert and ramp-up in US launches, including high-margin gCymbalta. With the recent acquisition in EU (Actavis assets) and US (Natrol), the share of high-margin formulations in total revenues has increased to ~80% (v/s 54% in FY10), positioning it among large-cap formulation players. Our target price of INR900 discounts ARBP's 1HFY19E EPS at 18x P/E multiple, which is:

- At par with its 3-year average P/E multiple, which is justified given its stronger business profile and earnings outlook.
- At >20% discount to sector average target P/E multiple, factoring in higher leverage and potential execution related risks.
- Implies a PEG of 1.0x (FY17-19E EPS CAGR of 17%).

We believe that the re-rating of the stock from single-digit P/E multiple to current levels partly factors in transition to formulations player, improved execution in the US and moderation in leverage (from 1.2x D/E in FY10 to 0.6x in FY17E). However, current valuations at 13x FY18E are still at ~30-35% discount to the sector average, which is unjustified, in our view. We argue for P/E re-rating for ARBP due to:

- Strong EPS outlook of % CAGR backed
- Strong free cash flow generation.
- Deleveraging of balance sheet, as we expect D/E to improve to 0.2x by FY19E.


Key catalysts to drive the stock's performance over medium term:

- Improvement in EU profitability (30% of business), led by deeper penetration in existing markets and site transfer to India.
- Launch of high-margin products in the US, including injectables (25+ launches over next 18 months) and controlled substance.
- Focus on high-margin triple combination ARV products in Africa (from FY16E).

Risks to our investment assumptions:


- Delay in ANDA approvals.
- Worsening of pricing environment in EU.
- Currency fluctuations both in USD and EUR terms.

Exhibit 12: P/E Band (x)



Source: Company, MOSL


Exhibit 13: P/E relative to Sensex



Source: Company, MOSL


Story in charts

Exhibit 14: Formulation led sales growth (INR b)




Source: Company, MOSL

Exhibit 15: US sales to grow at 14% CAGR over FY17-19E




Source: Company, MOSL

Exhibit 16: EBITDA growth to improve in FY17-19E




Source: Company, MOSL

Exhibit 17: EBITDA margins improving with product mix




Source: Company, MOSL

Exhibit 18: EPS growth to sustain at 17%




Source: Company, MOSL


Exhibit 19: Rich ANDA pipeline




Source: Company, MOSL

Exhibit 20: Improving cash flows to reduce debt


Source: Company, MOSL

Exhibit 21: Return ratios (%)


Source: Company, MOSL

Exhibit 22: R&D expense to increase going ahead


Source: Company, MOSL

Exhibit 23: Asset turnover improving

Source: Company, MOSL

Exhibit 24: EU business to grow at ~7%

Source: Company, MOSL

Exhibit 25: Formulation share getting bigger

Source: Company, MOSL

Financials and Valuations

Income Statement						(INR Million)		
Y/E Mar	2012	2013	2014	2015	2016	2017E	2018E	2019E
Net Sales	46,274	58,553	80,998	121,205	138,961	151,750	174,860	199,258
Change (%)	5.6	26.5	38.3	49.6	14.6	9.2	15.2	14.0
EBITDA	6,101	8,610	22,828	25,636	32,056	35,813	41,792	48,818
EBITDA Margin (%)	13.2	14.7	28.2	21.2	23.1	23.6	23.9	24.5
Depreciation	2,005	2,487	3,125	3,326	3,926	4,368	4,897	5,338
EBIT	4,096	6,122	19,703	22,310	28,130	31,445	36,895	43,481
Interest	1,028	1,313	1,079	843	927	815	926	747
Other Income	247	285	232	808	682	550	600	750
Extraordinary items	-5,445	-1,353	-2,031	-596	-660	430	0	0
PBT	-2,129	3,741	16,825	21,679	27,225	31,610	36,569	43,484
Tax	-888	827	3,635	5,966	7,444	8,377	10,057	11,741
Tax Rate (%)	41.7	22.1	21.6	27.5	27.3	26.5	27.5	27.0
Min. Int. & Assoc. Share	-6	-25	-38	-45	-39	-50	-55	-55
Reported PAT	-1,235	2,939	13,228	15,758	19,820	23,283	26,568	31,798
Adjusted PAT	1,939	2,939	13,228	15,758	19,820	23,283	26,568	31,798
Change (%)	-63.9	51.6	350.1	19.1	25.8	17.5	14.1	19.7

Balance Sheet						(INR Million)		
Y/E Mar	2012	2013	2014	2015	2016	2017E	2018E	2019E
Share Capital	582	582	583	584	585	585	585	585
Reserves	22,814	25,475	36,919	50,975	69,982	91,802	116,907	147,242
Net Worth	23,397	26,058	37,502	51,559	70,567	92,387	117,492	147,827
Debt	30,959	34,355	36,339	38,636	40,762	37,030	33,907	31,259
Deferred Tax	-16	680	2,054	2,058	2,364	2,411	2,459	2,508
Total Capital Employed	54,442	61,202	76,151	92,511	114,289	132,435	154,478	182,226
Gross Fixed Assets	30,863	37,080	41,066	53,821	61,224	74,224	81,224	88,224
Less: Acc Depreciation	8,916	11,246	14,613	17,405	19,713	24,081	28,977	34,315
Net Fixed Assets	21,947	25,834	26,453	36,416	41,511	50,143	52,246	53,909
Capital WIP	6,454	2,185	3,097	4,196	10,238	15,000	15,000	15,000
Investments	385	223	198	198	2	200	200	200
Current Assets	33,536	43,982	64,386	87,647	104,356	106,618	127,896	157,283
Inventory	15,456	19,236	23,675	36,113	40,881	44,103	50,245	56,338
Debtors	12,400	15,970	26,366	35,392	41,719	45,733	52,698	60,050
Cash & Bank	709	2,085	1,786	4,691	8,344	4,882	11,053	26,994
Loans & Adv, Others	4,972	6,692	12,559	11,451	13,412	11,900	13,900	13,900
Curr Liabs & Provns	7,880	11,576	18,747	36,587	42,704	40,413	41,751	45,052
Curr. Liabilities	7,174	10,685	17,389	34,161	40,641	39,488	40,826	44,127
Provisions	706	891	1,358	2,426	2,063	925	925	925
Net Current Assets	25,656	32,406	45,640	51,060	61,652	66,206	86,145	112,231
Total Assets	54,442	61,202	76,151	92,511	114,289	132,435	154,478	182,226

Financials and Valuations

Ratios

Y/E Mar	2012	2013	2014	2015	2016	2017E	2018E	2019E
Basic (INR)								
EPS	3.3	5.0	22.7	27.0	33.9	39.8	45.4	54.3
Cash EPS	6.8	9.3	28.1	32.7	40.6	47.3	53.8	63.5
Book Value	40.2	44.7	64.3	88.3	120.6	157.9	200.8	252.6
DPS	0.5	0.8	1.5	2.3	2.0	2.5	2.5	2.5
Payout (incl. Div. Tax.)	-23.6	14.9	6.6	8.3	5.9	6.3	5.5	4.6
Valuation(x)								
P/E	0.0	0.0	29.4	24.8	19.7	16.8	14.7	12.3
Price / Book Value	0.0	0.0	10.4	7.6	5.5	4.2	3.3	2.6
EV/Sales	0.0	0.0	5.3	3.5	3.0	2.8	2.4	2.0
EV/EBITDA	0.0	0.0	18.6	16.6	13.2	11.8	9.9	8.1
Dividend Yield (%)	0.1	0.1	0.2	0.3	0.3	0.4	0.4	0.4
Profitability Ratios (%)								
RoE	8.1	11.9	41.6	35.4	32.5	28.6	25.3	24.0
RoCE	4.9	8.7	23.3	20.4	20.8	19.5	19.4	19.5
RoIC	5.4	9.2	24.2	20.9	22.8	22.2	22.2	23.7
Turnover Ratios (%)								
Asset Turnover (x)	0.8	1.0	1.1	1.3	1.2	1.1	1.1	1.1
Debtors (No. of Days)	96	97	116	105	107	107	107	107
Inventory (No. of Days)	122	120	107	109	107	106	105	103
Creditors (No. of Days)	96	118	137	136	150	144	138	137
Leverage Ratios (%)								
Net Debt/Equity (x)	1.3	1.2	0.9	0.7	0.5	0.3	0.2	0.0

Cash Flow Statement

(INR Million)

Y/E Mar	2012	2013	2014	2015	2016	2017E	2018E	2019E
Adjusted EBITDA	6,101	8,610	22,828	25,636	32,056	35,813	41,792	48,818
Non cash opr. exp (inc)	247	285	232	808	682	550	600	750
(Inc)/Dec in Wkg. Cap.	-1,288	-5,374	-13,533	-2,515	-6,939	-8,016	-13,768	-10,145
Tax Paid	-327	-132	-3,635	-5,966	-7,444	-8,377	-10,057	-11,741
Other operating activities	-5,445	-1,353	-2,031	-596	-660	430	0	0
CF from Op. Activity	-712	2,036	3,863	17,367	17,696	20,401	18,567	27,683
(Inc)/Dec in FA & CWIP	-6,446	-2,106	-4,656	-14,389	-15,062	-17,762	-7,000	-7,000
Free cash flows	-7,157	-70	-793	2,978	2,633	2,638	11,567	20,683
(Pur)/Sale of Invt	0	-163	-25	0	-196	198	0	0
Others	0	0	0	0	0	0	0	0
CF from Inv. Activity	-6,446	-2,269	-4,681	-14,388	-15,259	-17,564	-7,000	-7,000
Inc/(Dec) in Net Worth	474	159	-910	-386	359	0	0	0
Inc / (Dec) in Debt	6,828	3,403	2,131	2,298	2,464	-3,721	-3,110	-2,636
Interest Paid	-1,028	-1,313	-1,079	-843	-927	-815	-926	-747
Divd Paid (incl Tax) & Others	-276	-641	379	-1,142	-681	-1,762	-1,360	-1,359
CF from Fin. Activity	5,998	1,608	520	-73	1,215	-6,298	-5,396	-4,742
Inc/(Dec) in Cash	-1,159	1,376	-298	2,905	3,652	-3,461	6,171	15,941
Add: Opening Balance	1,867	709	2,085	1,786	4,691	8,344	4,882	11,053
Closing Balance	708	2,084	1,786	4,691	8,343	4,883	11,053	26,994

Disclosures

This document has been prepared by Motilal Oswal Securities Limited (hereinafter referred to as Most) to provide information about the company (ies) and/or sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the selected recipient/s and does not constitute to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOST) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.

MOST and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a some companies covered by our Research Department. Our research professionals may provide input into our investment banking and other business selection processes. Investors should assume that MOST and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may educate investors on investments in such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting information. Our research professionals are paid on twin parameters of performance & profitability of MOST.

MOST generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOST generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing among other things, may give rise to real or potential conflicts of interest. MOST and its affiliated company(ies), their directors and employees and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the affiliates of MOST even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

Reports based on technical and derivative analysis center on studying charts company's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamental analysis. In addition MOST has different business segments / Divisions with independent research separated by Chinese walls catering to different set of customers having various objectives, risk profiles, investment horizon, etc, and therefore may at times have different contrary views on stocks sectors and markets.

Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOST or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOST or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOST or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOST's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOST and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOST and/or its affiliates from doing so. MOST or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOST or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This report is intended for distribution to institutional investors. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents.

Most and its associates may have managed or co-managed public offering of securities, may have received compensation for investment banking or merchant banking or brokerage services, may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Most and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

Subject Company may have been a client of Most or its associates during twelve months preceding the date of distribution of the research report

MOST and/or its affiliates and/or employees may have interests/positions, financial or otherwise of over 1% at the end of the month immediately preceding the date of publication of the research in the securities mentioned in this report. To enhance transparency, MOST has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

Motilal Oswal Securities Limited is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014. SEBI Reg. No. INH000000412

Pending Regulatory inspections against Motilal Oswal Securities Limited:

SEBI pursuant to a complaint from client Shri C.R. Mohanraj alleging unauthorized trading, issued a letter dated 29th April 2014 to MOSL notifying appointment of an Adjudicating Officer as per SEBI regulations to hold inquiry and adjudge violation of SEBI Regulations; MOSL replied to the Show Cause Notice whereby SEBI granted us an opportunity of Inspection of Documents. Since all the documents requested by us were not covered we have requested to SEBI vide our letter dated June 23, 2015 to provide pending list of documents for inspection.

List of associate companies of Motilal Oswal Securities Limited - [Click here to access detailed report](#)

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOST research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues

Disclosure of Interest Statement

- Analyst ownership of the stock
- Served as an officer, director or employee -

AUROBINDO PHARMA

No
No

A graph of daily closing prices of securities is available at www.nseindia.com and <http://economictimes.indiatimes.com/markets/stocks/stock-quotes>

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOST & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong: This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part 1 of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons.

This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act (FAA) read with regulation 17(1)(d) of the Financial Advisers Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time.

In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:

Varun Kumar

Varun.kumar@motilaloswal.com

Contact : (+65) 68189232

Office Address: 21 (Suite 31), 16 Collyer Quay, Singapore 04931



Motilal Oswal Securities Ltd

Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025

Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com